TW202037597A - 用於製備丁基原啡因之方法 - Google Patents

用於製備丁基原啡因之方法 Download PDF

Info

Publication number
TW202037597A
TW202037597A TW109106564A TW109106564A TW202037597A TW 202037597 A TW202037597 A TW 202037597A TW 109106564 A TW109106564 A TW 109106564A TW 109106564 A TW109106564 A TW 109106564A TW 202037597 A TW202037597 A TW 202037597A
Authority
TW
Taiwan
Prior art keywords
less
butylprophine
free base
acetate
blend
Prior art date
Application number
TW109106564A
Other languages
English (en)
Chinese (zh)
Inventor
希 杭特利
艾瑞克 卡泰斯托
賀吉 瑞斯克
亞奇安納 夏瑪
加克 史迪密斯特
Original Assignee
美商羅德科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商羅德科技公司 filed Critical 美商羅德科技公司
Publication of TW202037597A publication Critical patent/TW202037597A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
TW109106564A 2015-03-10 2016-03-10 用於製備丁基原啡因之方法 TW202037597A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
US62/131,114 2015-03-10

Publications (1)

Publication Number Publication Date
TW202037597A true TW202037597A (zh) 2020-10-16

Family

ID=55524412

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109106564A TW202037597A (zh) 2015-03-10 2016-03-10 用於製備丁基原啡因之方法
TW105107434A TWI699367B (zh) 2015-03-10 2016-03-10 用於製備丁基原啡因之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105107434A TWI699367B (zh) 2015-03-10 2016-03-10 用於製備丁基原啡因之方法

Country Status (19)

Country Link
US (6) US10406152B2 (enExample)
EP (1) EP3283490A1 (enExample)
JP (2) JP6660399B2 (enExample)
KR (2) KR20200045010A (enExample)
CN (1) CN107660207B (enExample)
AR (1) AR103902A1 (enExample)
AU (2) AU2016230750B2 (enExample)
BR (1) BR112017019357A2 (enExample)
CA (2) CA2977732C (enExample)
CO (1) CO2017009130A2 (enExample)
EA (1) EA201792014A1 (enExample)
IL (1) IL254384A0 (enExample)
MA (1) MA45902A (enExample)
MX (1) MX2017011606A (enExample)
NZ (1) NZ735736A (enExample)
PH (1) PH12017501641A1 (enExample)
SG (1) SG11201707350TA (enExample)
TW (2) TW202037597A (enExample)
WO (1) WO2016142877A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512046A (ja) 2013-03-15 2016-04-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ベンジルイソキノリンアルカロイド（ｂｉａ）産生微生物、ならびにそれらを作製および使用する方法
US11124814B2 (en) 2013-11-04 2021-09-21 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same
SG11201707350TA (en) * 2015-03-10 2017-10-30 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107614688B (zh) 2015-05-04 2023-02-28 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物及其制备和使用方法
JP7266966B2 (ja) 2015-05-08 2023-05-01 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー エピメラーゼ及びベンジルイソキノリンアルカロイドを産生する方法
EP3529355A4 (en) 2016-10-18 2020-07-08 Antheia, Inc. PROCESSES FOR THE PRODUCTION OF NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS
JP7199417B2 (ja) 2017-08-03 2023-01-05 アンテイア インコーポレイテッド 遺伝子操作されたベンジルイソキノリンアルカロイドエピメラーゼおよびベンジルイソキノリンアルカロイドの生成方法
KR102839314B1 (ko) * 2018-05-11 2025-07-29 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
KR20210138642A (ko) 2019-03-08 2021-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 비-식물 숙주 세포를 생산하는 트로판 알칼로이드(ta), 및 이의 제조 및 사용 방법
CN119421713A (zh) * 2022-06-24 2025-02-11 昱展新药生技股份有限公司 丁丙诺啡的稳定医药组合物、其制备方法及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (enExample) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
ES2393221T3 (es) 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
US7982056B2 (en) 2006-12-11 2011-07-19 Alcon Research, Ltd. Substantially pure fluorescein
WO2010016219A1 (ja) * 2008-08-05 2010-02-11 株式会社メドレックス 塩基性薬効成分の脂肪酸塩、安息香酸塩を含有する外用剤とその製造方法
WO2011005452A1 (en) * 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the enrichment of buprenorphine using chromatographic techniques
ES2562643T5 (es) * 2010-09-30 2019-05-24 Astrazeneca Ab Conjugado de naloxol-peg cristalino
AR089201A1 (es) * 2011-12-12 2014-08-06 Lohmann Therapie Syst Lts Sistema de suministro transdermico
EP2844236B1 (en) 2012-04-17 2018-12-19 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014102591A1 (en) * 2012-12-31 2014-07-03 Rhodes Technologies PROCESS FOR PREPARING 7β-SUBSTITUTED 6α,14α -ETHENOMORPHINANS AND 7β-SUBSTITUTED 6α,14α-ETHANOMORPHINANS
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
SG11201707350TA (en) * 2015-03-10 2017-10-30 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine

Also Published As

Publication number Publication date
CO2017009130A2 (es) 2017-11-21
US20180162866A1 (en) 2018-06-14
AU2016230750B2 (en) 2019-05-30
TWI699367B (zh) 2020-07-21
US9926329B2 (en) 2018-03-27
US10874662B2 (en) 2020-12-29
EP3283490A1 (en) 2018-02-21
US20210046066A1 (en) 2021-02-18
MA45902A (fr) 2019-06-19
JP6660399B2 (ja) 2020-03-11
AU2019203308A1 (en) 2019-05-30
CA2977732C (en) 2021-02-23
JP2018507882A (ja) 2018-03-22
NZ735736A (en) 2019-02-22
US20190314364A1 (en) 2019-10-17
TW201639856A (zh) 2016-11-16
PH12017501641A1 (en) 2018-02-12
US10406152B2 (en) 2019-09-10
MX2017011606A (es) 2017-10-26
US20180235955A1 (en) 2018-08-23
AR103902A1 (es) 2017-06-14
US20190298713A1 (en) 2019-10-03
CN107660207A (zh) 2018-02-02
CA3104099A1 (en) 2016-09-15
AU2016230750A1 (en) 2017-10-12
KR20200045010A (ko) 2020-04-29
US20170197975A1 (en) 2017-07-13
CA2977732A1 (en) 2016-09-15
CN107660207B (zh) 2020-09-29
WO2016142877A1 (en) 2016-09-15
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
IL254384A0 (en) 2017-11-30
JP2020033359A (ja) 2020-03-05
US10278967B2 (en) 2019-05-07
EA201792014A1 (ru) 2018-01-31
BR112017019357A2 (pt) 2018-06-05
KR20170137738A (ko) 2017-12-13

Similar Documents

Publication Publication Date Title
TWI699367B (zh) 用於製備丁基原啡因之方法
US10519176B2 (en) Crystalline forms
CN102781441A (zh) 大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法
TWI270374B (en) Crystalline polymorph of irinotecan hydrochloride, a process for preparing the same, a pharmaceutical composition comprising it and its use as a therapeutic agent
TWI326684B (enExample)
JP3190679B2 (ja) 複素環式化学
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
US20060046993A1 (en) Crystalline polymorphic form of irinotecan hydrochloride
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP2024546098A (ja) ラベキシモド化合物
WO2022247885A9 (zh) 三并杂环类化合物的结晶和盐及其应用
WO2009061336A1 (en) Amorphous and crystalline forms of ibandronate disodium
CN101233141A (zh) 子囊霉素晶形及其制备
CN118359591A (zh) 一种化合物与氨基酸的固体形式及其制备方法和用途
CN118284600A (zh) 依利格鲁司他可药用盐及其晶型
CN116867497A (zh) 一种药用组合物及其制备方法和用途